Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Authors
Keywords
-
Journal
Molecular Oncology
Volume 6, Issue 2, Pages 222-236
Publisher
Wiley
Online
2012-02-25
DOI
10.1016/j.molonc.2012.02.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- aTTom (adjuvant Tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results
- (2017) R. G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
- (2011) Uwe Güth et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
- (2011) P-L Jerevall et al. BRITISH JOURNAL OF CANCER
- American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer
- (2011) Jennifer J. Griggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Endocrine Therapy for Breast Cancer: Don't Ditch the Switch!
- (2011) S. Puhalla et al. JNCI-Journal of the National Cancer Institute
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- (2011) Eitan Amir et al. JNCI-Journal of the National Cancer Institute
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- (2011) Cornelis JH van de Velde et al. LANCET
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- Pharmacogenetics of Endocrine Therapy for Breast Cancer
- (2010) Michaela J. Higgins et al. Annual Review of Medicine
- Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
- (2010) Kathleen I. Pritchard et al. BREAST CANCER RESEARCH AND TREATMENT
- The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
- (2010) Michael Knauer et al. BREAST CANCER RESEARCH AND TREATMENT
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
- (2010) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
- (2010) James N. Ingle et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
- (2010) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
- (2010) Michaela J. Higgins et al. Current Oncology Reports
- A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)
- (2009) V. H. C. Bramwell et al. ANNALS OF ONCOLOGY
- Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users
- (2009) A. S. Dieudonné et al. BREAST CANCER RESEARCH AND TREATMENT
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
- (2009) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer
- (2009) Matthew J. Ellis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
- (2008) Beat Thürlimann et al. BREAST CANCER RESEARCH AND TREATMENT
- Validation of 70-gene prognosis signature in node-negative breast cancer
- (2008) J. M. Bueno-de-Mesquita et al. BREAST CANCER RESEARCH AND TREATMENT
- Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials
- (2008) D. T. Ross et al. CLINICAL CANCER RESEARCH
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
- (2008) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search